80. Integrating expert knowledge for somatic variant interpretation: Achievements and future directions of ClinGen somatic

PRODUCTS USED

Variant Libraries
Read Full Article

ABSTRACT

Introduction Consistent and accurate interpretation of the clinical significance (diagnosis, prognosis, and treatment response) and oncogenicity of somatic variants found in tumors remains a major challenge requiring community consensus and structured guidance. Clinical Genome Resource (ClinGen) Somatic Cancer is heading a multifaceted collaborative effort to address this challenge. ClinGen Somatic Cancer Variant Curation Expert Panels (SC-VCEPs) are enriching the Clinical Interpretations of Variants in Cancer (CIViC; civicdb.org) knowledgebase with high-quality assertions addressing the clinical significance and oncogenicity of somatic variants. Building on the success of our expert knowledgebase, we are leveraging improved genomic data sharing and natural language processing to expand our efforts, advance research, and propel precision medicine. Methods Three Clinical Domain Working Groups (CDWG) operate within ClinGen Somatic: Pediatric Cancer, Solid Tumor, and Hematologic Cancer. These CDWGs facilitate membership growth, engage field experts, and direct targeted curation projects. SC-VCEPs exist under CDWGs and follow the rigorous ClinGen 4-step approval process where they must define their scope (Step 1), develop clinical significance and oncogenicity classification guidance (Step 2), pilot their guidance (Step 3), and establish sustainability protocols (Step 4). In step 2, SC-VCEPs tailor AMP/ASCO/CAP and ClinGen/CGC/VICC Oncogenicity guidelines, or create new classification guidance when necessary, to aid granular assessment of their genomic alterations of interest. Somatic CDWGs and SC-VCEPs curate evidence from the published literature and enter summaries of the current state of the field as Assertions into the publicly available and open access CIViC platform. A survey of ClinGen Somatic membership and the cancer community provided insight regarding challenging areas of somatic variant interpretation to facilitate the expansion of SC-VCEPs and our knowledgebase. Results Eight SC-VCEPs are currently working through the 4-step process with three tailoring guidelines (MAPK/ERK, Histone H3, EGFR*), four in the pilot phase (FGFR, FLT3, Established Significance, BCR::ABL1-like*) and one finalizing sustained curation plans (NTRK*). All eight SC-VCEPs evaluate oncogenes with five focused on SNVs and three on fusions*. Over the past year, ClinGen Somatic CDWGs and SC-VCEPs have entered over 250 evidence items and 50 Assertions into CIViC, leading all CIViC Organizations in submissions and moderations. Survey responses directed us to areas of need in somatic interpretation like seeking the development of SC-VCEPs for tumor suppressor genes (e.g., EZH2, PTEN) and structural variants (e.g., ALK rearrangements). Discussion/Conclusion These eight SC-VCEPs barely address the vast and complex array of genes and somatic variant types that influence cancer progression. Yet, the power of our expert-led biomedical knowledgebase initiative is clearly demonstrated through high-quality assertions placed in CIViC, which will continue to expand as SC-VCEPs complete their pilots. We envision building on this early success through targeted expansion of SC-VCEPs by prioritizing the greatest areas of need in somatic interpretation as indicated by the cancer community.

Read Full Article

PRODUCTS USED

Variant Libraries